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Abstract: Chronic hepatosplenomegaly, which is known
to have a complex aetiology, is common amongst
children who reside in rural areas of sub-Saharan Africa.
Two of the more common infectious agents of hepato-
splenomegaly amongst these children are malarial infec-
tions and schistosomiasis. The historical view of hepato-
splenomegaly associated with schistosomiasis is that it is
caused by gross periportal fibrosis and resulting portal
hypertension. The introduction of ultrasound examina-
tions into epidemiology studies, used in tandem with
clinical examination, showed a dissociation within en-
demic communities between presentation with hepato-
splenomegaly and ultrasound periportal fibrosis, while
immuno-epidemiological studies indicate that rather than
the pro-fibrotic Th2 response that is associated with
periportal fibrosis, childhood hepatosplenomegaly with-
out ultrasound-detectable fibrosis is associated with a
pro-inflammatory response. Correlative analysis has
shown that the pro-inflammatory response is also
associated with chronic exposure to malarial infections
and there is evidence of exacerbation of hepatospleno-
megaly when co-exposure to malaria and schistosomiasis
occurs. The common presentation with childhood hepa-
tosplenomegaly in rural communities means that it is an
important example of a multi-factorial disease and its
association with severe and subtle morbidities underlies
the need for well-designed public health strategies for
tackling common infectious diseases in tandem rather
than in isolation.
Introduction
In 1960, Walters and McGregor wrote ‘‘throughout the tropical
belt hepatic disease is rife; its aetiology has been attributed severally
to malaria, to malnutrition, to infection or to the combined action of
all three’’ [1]. Half a century later it could be argued that in the
tropics hepatic disease is still rife and, although widespread, our
understanding of the aetiology, underlying mechanisms, and
consequences remains poor. Schistosomiasis is a common cause of
hepatosplenomegaly in the tropics, with its severest morbidity being
hepatosplenomegaly associated with gross periportal fibrosis, also
known, after the clinician who first described it, and its distinctive
appearance, as Symmer’s pipe-stem fibrosis. However, the
introduction of portable ultrasound showed that for the majority
of schoolchildren in schistosomiasis-endemic areas, the mechanism
underlying hepatosplenomegaly is not periportal fibrosis. Here we
assess recent clinical and immunological evidence, along with that
published in the 1960s, ‘70s, and ‘80s, for dissociation of periportal
fibrosis from presentation with hepatosplenomegaly in school-aged
children—a morbidity that is now encompassed by the World
Health Organization (WHO) Working Group on Schistosomiasis’
definition of ‘‘subtle’’ morbidity [2]. We hope to highlight that
schistosomiasis mansoni–associated morbidity is not predominantly
periportal fibrosis and that another, widespread morbidity,
influenced not only by schistosomiasis but other infectious agents,
is affecting the lives of millions of children in sub-Saharan Africa.
Methods
Data for this review was collected by searches in NCBI PubMed
and from the references of relevant articles. Numerous articles
were identified from the extensive files of the authors. The
population-based studies included examine either a broad age
range from school-aged through adulthood, or concentrate solely
on morbidity of school-aged children. The criteria were relaxed
for references relating to immune responses associated with
periportal fibrosis when studies examining adult cohorts are
referenced.
Schistosomiasis-Associated Periportal Fibrosis
As the definitive site of Schistosoma mansoni is the mesenteric
veins, it is necessary for eggs to transverse the gut wall, causing gut
pathology associated with diarrhoea, sometimes bloody, and
abdominal pain [3]. However, released eggs can be swept by the
host’s circulation into the liver, becoming trapped. The immune
response to trapped eggs, characterised by T helper 2 (Th2)-
mediated granulomatous reactions can, over years, cause peripor-
tal fibrosis [4]. Long-term deposition of thick fibrotic material
around the hepatic vasculature restricts blood flow, leading to
portal hypertension. This is accompanied in early stages by a firm,
enlarged liver with a smooth surface, while in later stages the liver
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can become smaller and nodular. The symptoms of portal
hypertension—passive congestion of blood flow leading to
splenomegaly, presence of ascites and development of varices in
collateral veins, and, when these rupture, haematemesis—have all
been observed in severe hepatosplenic schistosomiasis.
In a series of autopsy studies carried out by Alan Cheever in the
1960s and 1970s on S. mansoni–associated hepatic pathology, in all
deaths caused by complications of portal hypertension, gross
periportal fibrosis was present [5,6], with haemorrhaging of
oesophageal varices being the most common cause of death [5].
Periportal fibrosis was linked to infection intensity, as indicated by
worm recovery on blood perfusion [6,7]. Infection intensity is not
the sole factor in development of severe hepatic schistosomiasis.
The autopsy studies reported differences in prevalence of
periportal fibrosis between ethnic groups [5], suggesting that
development of periportal fibrosis is under genetic control. It is
now known that North Africans are more susceptible to periportal
fibrosis than sub-Saharan Africans, even when infection intensities
are greater in sub-Saharan cohorts [8,9]. Familial patterns of
disease also occur [10] and genetic studies have identified gene
polymorphisms associated with periportal fibrosis [11,12].
Schistosomiasis–Associated Morbidity in Endemic
Communities
Cheever said of his findings, ‘‘trends existing in the community
of an endemic area may not be evident in this autopsy series, and
vice versa.’’ Prior to the introduction of ultrasound, severity of S.
mansoni–associated morbidity was accessed using the presence and
extent of hepatosplenomegaly by palpation. After the findings of
Cheever’s work, enlargement of the liver was thought to be due to
periportal fibrosis and enlargement of the spleen due to passive
congestion and reticuloendothelial hyperplasia [4]. In several
community epidemiology studies conducted in different parts of
the world, and among different ethnic groups, prevalence of
hepatomegaly peaked in older children and adolescents, the age
group in which S. mansoni infection intensity peaks [10,13–15]. The
prevalence of hepatomegaly also increased as S. mansoni infection
intensities increased [10,13–17]. Clinical presentation was of
dominant left liver lobe enlargement, of firm consistency [18], with
a significant relationship between extent of enlargement and
infection intensities being reported [13,14,16].
In the 1980s portable ultrasound machines were introduced into
epidemiological research of schistosome-associated morbidity.
Ultrasonography is now the method of choice for detecting
periportal fibrosis in epidemiological studies, as it is distinctive and
clearly visible (Figure 1), and sensitivity is such that mild cases can
be detected [19]. An international protocol has been established
and extensively tested in various endemic situations [20]. The
protocol is based on coding of imaged patterns; grades C and D
indicate mild fibrosis that often resolves with treatment, and grades
E and F represent gross fibrosis, often with sequealae related to
portal hypertension, that rarely resolves with treatment [21].
Under the protocol a series of other measurements—liver and
spleen size, wall thickness of the second order portal branches, and
portal vein diameters—are taken. Presence of collaterals and
ascites are also recorded.
Utilisation of ultrasonography in community-based studies
showed that prevalence of periportal fibrosis peaks in adulthood,
with cases detectable into middle age, even when S. mansoni
infection intensity drops dramatically in early adulthood (Figure 2)
[22–25]. Some studies do, in agreement with the autopsy studies,
find an association between periportal fibrosis and S. mansoni
infection intensities; however, the strength of S. mansoni intensity’s
influence on the presence of periportal fibrosis is weak in
comparison to that of age and sex [9,23,25,26], and other studies
fail to find an association [8,22,27,28]. The lack of consensus
about the influence of infection intensities on periportal fibrosis
Figure 1. Ultrasound image of periportal fibrosis in S. mansoni infection. The image was taken during ultrasound examination of a study
cohort from Piida village on the shores of Lake Albert, Uganda, in March 2004 and illustrates liver texture pattern C with ‘‘pipe-stems.’’
doi:10.1371/journal.pntd.0001149.g001
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and periportal fibrosis occurring in adulthood, often in the fourth
and fifth decades of life [9,22,23], indicate that development of
fibrosis is largely dependent on long-term exposure to S. mansoni, a
conclusion supported by duration of residence in endemic areas,
rather than age per se, being strongly associated with presence of
periportal fibrosis [24]. Due to the importance of duration of
infection in the development of periportal fibrosis, it is rare in
school-aged children and when present is usually mild
[9,23,24,26,29].
Taking an overview of clinical-based studies carried out in the
1970s and ‘80s and ultrasound studies conducted from the late
1980s onwards allows us to see that within communities the
prevalence and extent of hepatosplenomegaly with age, in the
majority of endemic situations, mirrors the characteristic infection
intensity curve, while periportal fibrosis is more common in an
older age group (Figure 2). Hepatosplenomegaly is often
significantly associated with S. mansoni infection intensities, a
relationship that has been harder to establish for periportal
fibrosis. Studies that have used clinical and ultrasound examina-
tions in tandem confirm that many children with S. mansoni–
associated hepatosplenomegaly show no signs of periportal fibrosis
[28,30,31]. This supports the proposal made in 1987 that ‘‘juvenile
hepatomegaly is probably not due to a definitive fibrotic process,
but rather to immune responses’’ [15].
Figure 2. Comparison of S. mansoni egg counts (boxplots), liver size (solid line), and prevalence of severe, non-reversible (pattern E/
F) periportal fibrosis (dashed line) by age. Data is from a randomised cohort selected from the inhabitants of Booma village on the shores of
Lake Albert, Uganda. The sole criterion for selection was born in Booma or over 10 years of residence. The left liver lobe was measured in the
parasternal line by ultrasound and was standardised for height by linear regression. A comparison of morbidity amongst a larger population from this
village and the neighbouring one is published in detail in [24].
doi:10.1371/journal.pntd.0001149.g002
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Childhood Hepatosplenomegaly: An
Inflammatory Process
The mechanism behind periportal fibrosis is likely related to
granulomas that form around eggs trapped within the liver, a
process well researched in the mouse model. In the mouse IL-13 is
important, upregulating arginase-1 in granuloma macrophages.
Arginase-1 uses arginine to make L-ornithine, an intermediate of
an essential amino acid in collagen production, proline, while
IFNc upregulates the production of inducible nitric oxide
synthase, a pathway that uses arginine as a substrate, inhibiting
the production of proline [32]. In humans, little IL-13 is produced
by whole blood cultures stimulated with schistosome egg antigen
(SEA), suggesting that IL-13 production is successfully down-
regulated in the majority of individuals [33,34]. However, higher
levels of SEA-specific IL-13 [35,36] and lower levels of SEA-
specific IFNc are associated with periportal fibrosis [37,38].
Periportal fibrosis is therefore likely due to a sustained Th2
response [39]. In contrast, children who present with hepato-
splenomegaly in the absence of periportal fibrosis have low levels
of SEA-specific Th2 cytokines, IL-4, IL-5, and IL-13 [40]. Instead,
childhood hepatosplenomegaly is associated with high levels of
TNF and IFNc in peripheral blood mononuclear cell cultures
[41], and SEA-stimulated whole blood cultures predominantly
produced TNFa and the regulatory cytokines IL-6 and TGFb.
Lower levels of IL-6 and TGFb to schistosome antigen
preparations are associated with substantial enlargement of the
liver, suggesting a potential lack of regulation [40].
The Role of Co-Exposure to Malaria
Hepatosplenomegaly can occur during acute malaria attacks,
due to reticuloendothelial and lymphoid hyperplasia [42]. Around
half of cases of hepatosplenomegaly associated with acute malaria
resolve within 2 weeks of treatment and others have partial
regression within the same time scale [43,44]. When treatment
fails to clear parasitaemia, or when time between attacks is too
short for full resolution, hepatosplenomegaly is persistent [43]. As
immunity to malaria develops, time between malaria attacks
increases and a corresponding drop in prevalence of hepato-
splenomegaly occurs [42,45]. In community studies in The
Gambia during the 1950s and 1960s, age-prevalence curves of
hepatomegaly followed the pattern of the age-prevalence curve for
malaria parasitaemia. The consistency of the liver was of three
types: soft, common in infants; rubbery with a defined edge, most
prevalent in children 1–6 years of age; and firm to hard, often of
considerable enlargement and most prevalent in older children,
adolescents, and adults [46]. Needle biopsy material from children
with firm to hard hepatomegaly showed coarse fibrosis around
periportal tracts, but no excess in cellular infiltration or deposits of
malaria pigment [47]. Young children also had localised fibrotic
out growths but, in contrast to older children, they also had
lymphocyte infiltrations in hepatic sinusoids, hyperplasia of
Kupffer cells, and deposits of malaria pigment were present [1].
With ongoing chronic exposure to malaria being an aetiological
agent of hepatosplenomegaly in school-aged children, the age
group in which the prevalence and extent of schistosomiasis-
related hepatosplenomegaly is also at its peak, the two infections
could exacerbate the hepatosplenomegaly caused by each other. In
one early study, infection with both parasites, rather than either
infection alone, was associated with the presence of hepatospleno-
megaly [48]. Latterly, this has been addressed further in a series of
studies on childhood hepatosplenomegaly conducted in the
neighbouring districts of Machakos and Makueni in Kenya.
The first, a cross-sectional study, compared prevalence of
hepatosplenomegaly in school-aged children from Kangundo,
Machakos District, and Kambu, Makueni District. S. mansoni
infection intensities were comparable, and prevalence of hepato-
splenomegaly within both communities was significantly associated
with S. mansoni infection intensities, but prevalence was greater in
Kambu [49]. In Kambu some cases of hepatosplenomegaly were
very severe (Figure 3), and the children were hospitalised for
further examination. Interactions between S. mansoni and common
gut parasites could not explain the difference as there was no
significant difference in prevalence of the common gut helminths
or protozoa, and there was no association between the presence of
S. mansoni and any of the gut parasites [50]. One major difference
between Kangundo and Kambu, due to altitude, is the importance
of malaria as a public health problem. Although current
microscopically detectable malaria parasitemia was not directly
associated with hepatosplenomegaly, it was suggested that chronic
exposure to malaria could be exacerbating hepatosplenomegaly
[49]. This suggestion was substantiated by a case control study in
which children with hepatosplenomegaly had elevated plasma
levels of IgG3 specific for Plasmodium falciparum schizont antigen
(Pfs) [51]. Pfs-IgG3 levels are representative of relative age and
geographical exposure to malarial infections [52].
In children selected on the basis of having an enlarged liver,
both the extent of the liver and the spleen were significantly
associated with S. mansoni infection intensities. Ultrasound
examinations showed that hepatosplenomegaly was present in
the absence of periportal fibrosis [30]. During a 3-year follow-up
period, although significant regression of hepatosplenomegaly
occurred post-treatment for schistosomiasis, full resolution of
hepatosplenomegaly did not occur in all children, even though the
Kambu River, the one site of S. mansoni transmission, had been
mollluscicided regularly, limiting population numbers of the
Biomphalaria snail intermediate host [53]. Pfs-IgG3 responses were
elevated in children who lived close to the Kambu River and it was
these children, who also had high S. mansoni infection intensities,
who had the largest spleens at baseline [54] and the poorest rate of
resolution [55]. Finally, children in two neighbouring primary
schools, one with a catchment area with S. mansoni transmission
and the other in an area where S. mansoni transmission is abrogated
due to the lack of habitat for the intermediate host, presented with
a comparable prevalence of hepatosplenomegaly. The presence of
hepatosplenomegaly was associated with plasma levels of Pfs-IgG3,
but children with S. mansoni infections had greater liver and spleen
enlargement; for the liver this exacerbation was S. mansoni infection
intensity dependent [31].
Exacerbation of the Inflammatory Process with
Co-Exposure to Schistosomiasis and Malaria
Higher levels of the pro-inflammatory cytokine IL-12p70 in
plasma are associated with hepatosplenomegaly [40]. Levels of the
regulatory cytokine IL-10 and soluble TNF receptor I (sTNF-RI)
and sTNF-RII are also significantly higher in children with
hepatosplenomegaly [40,41]. As sTNF-RI and sTNF-RII are
antagonistic soluble receptors, induced by TNFa itself [56,57], and
IL-10 is induced during a pro-inflammatory response as a
feedback control mechanism [58,59], it is likely that these
responses reflect an attempt to control a pro-inflammatory
response. In Mali, sTNF-RII levels are elevated in children co-
infected with P. falciparum and Schistosoma haematobium, either in
comparison with children who only have malaria [60], or in
comparison with children who only have S. haematobium [61]. IL-
12p70, IL-10, and sTNF-RII are strongly correlated with the
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Pfs-IgG3 malaria exposure marker, and levels of IL-10 and sTNF-
RII are significantly greater in children who are co-infected with P.
falciparum and S. mansoni [62]. Furthermore, Th2 responses to SEA
are down-regulated by P. falciparum infection [40]. The results of
cytokine analysis, from cells stimulated with schistosome antigens
ex vivo and from plasma levels, therefore, indicate that childhood
hepatosplenomegaly is associated with a pro-inflammatory re-
sponse to which both S. mansoni and P. falciparum infections
contribute. Whether the exacerbation is purely additive or
synergistic, remains to be clarified; however, the down-regulation
Figure 3. Hepatosplenomegaly in a school-aged girl with schistosomiasis, Kambu, Makueni District, Kenya. The photograph was taken
during field studies carried out in 1988. Extent of palpable organs are indicated by chalk markings. The scarification seen is from ‘‘treatment’’ of
organomegaly administered by traditional healers. The traditional healer will make small cuts at the edge of the palpable organ. When several rows of
scars are seen (as shown), this represents repeat ‘‘treatment’’ and therefore shows the progression of organ enlargement with time.
doi:10.1371/journal.pntd.0001149.g003
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of SEA-specific Th2 responses in children infected with P.
falciparum, a finding also reported from mouse models of
malaria/schistosome co-infection [63,64], does indicate interac-
tion at the immunological level between the two parasites.
Sequelae of Childhood Hepatosplenomegaly
During an early cross-sectional study in Maukeni District, some
cases of hepatosplenomegaly in Kambu were of a severity that the
children were hospitalised for further examination. Eighteen were
found to have oesophageal varices, a sub-set of whom did not have
ultrasound detectable periportal fibrosis [49]. Systematic ultra-
sound assessment in later field studies showed that none of the
children included had detectable periportal fibrosis [30,31].
However, following fully the Niamey protocol to analyse data,
with comparisons being made to S. mansoni uninfected Senegalese
who serve as a standard reference population, 28% of the children
examined were classed as having portal hypertension. In a later
cross-sectional study, due to ongoing debate as to the suitability of
the Senegalese reference population and the reproducibility of
some of the more difficult measurements [9,65,66], inter- and
intra-observer robust portal vein diameter measurements [65],
standardised internally for height, were used and were both
greatest amongst children who had hepatosplenomegaly, and
related to Pfs-IgG3 levels and S. mansoni infection intensities [67].
The long-term consequences of this dilation of the portal vein are
poorly understood, but previous findings that ascites and varices
can be present in the absence of periportal fibrosis indicates that
‘‘subtle’’ morbidity, in this case hepatosplenomegaly, may have
health consequences that are far from subtle.
As long-term insults to health can result in stunting of growth
[68,69], and childhood hepatosplenomegaly is of a chronic nature,
nutritional status has been assessed. Comparison of the nutritional
status of children in a high morbidity area with that of children in
the low morbidity area showed poorer height-for-age amongst the
former, being worst in children with hepatomegaly. However, diet
was also poorer and as it could not be determined whether poor
nutrition was involved in the development of hepatomegaly, or
hepatomegaly was causing poor nutritional status, nutrition could
not be discounted as an aetiological agent of hepatomegaly [70].
More recently poor height-for-age, determined by comparison
with the CDC 2000 standards, was found to be highly prevalent,
with 59.4% of children in an endemic area being classified as
stunted. Stunting was most prevalent amongst children with
organomegaly, reaching 75.4% amongst children positive for S.
mansoni and with hepatosplenomegaly. In the interim between
these two studies a school-feeding program was introduced,
removing the influence of current poor nutritional intake [67].
The implication is that the underlying process causing hepato-
splenomegaly is also having a detrimental effect on the growth of
children. The mechanism is purely speculative, but one proposal is
that inflammatory cytokines produced during childhood hepato-
splenomegaly are adversely effecting the production of the growth
hormone insulin growth factor one by the liver.
Other Potential Aetiological Agents
In the studies carried out in Machakos and Makueni Districts,
visceral leishmaniasis was discounted as no outbreaks occurred
during the 15 years that this series of studies spanned; and although
investigated by researchers at the Kenya Research Institute, there is
no evidence that brucellosis is contributing, even though contact
with livestock is the norm (A. E. Butterworth, personal communi-
cation). Other infectious agents include the chronic hepatitis viruses
B and C. In the Machakos/Makueni studies no cases of
discompensated cirrhosis were observed, and fine, compensated
cirrhosis is not detectable by ultrasound. However, in many of the
African populations studied the prevalence of hepatosplenomegaly
is too great, and the age group in which it is observed too young, for
viral hepatitis to be a major contributing factor [71,72].
Although circumstantial evidence, there was an observed
improvement in the health of children from Makueni after the
introduction of the school-feeding program subtle, long-term
health consequences were observable, but the severe consequences
of ascites and varices were no longer seen. Poor nutrition therefore
cannot be discounted as an important modifier of hepatospleno-
megaly and its consequences.
In 1987, Kevin De Cock, working at the Kenyatta National
Hospital in Nairobi, reported that Akamba, the main tribal group
in Machakos and Makueni Districts, had a higher incidence of
idiopathic portal hypertension than other tribal groups in Kenya.
He concluded that this could be attributable to an environmental
cause [73]. This tribal group is also reported to have a higher
incidence of hepatocellular cancer [74]. Chronic aflatoxin
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exposure is known to increase the risk of hepatocellular cancer
[75], though it is not known whether chronic aflatoxin exposure
causes hepatomegaly in the absence of hepatocellular cancer. In
Machakos and Makueni Districts, as in large parts of sub-Saharan
Africa, maize is the staple food source, and this crop, along with
groundnut, another common food staple, is particularly susceptible
to growth of Aspergillus spp., the fungus that produces aflatoxin [75].
We have recently undertaken collaborative analysis to determine
the role of chronic exposure to aflatoxin, and results indicate that
aflatoxin is contributing to the hepatosplenomegaly observed (Y-Y
Gong, unpublished data). School-aged hepatosplenomegaly is
therefore an example of a multi-factorial disease, attributable to a
number of aetiological agents that are associated with poverty and
widespread in sub-Saharan Africa.
Conclusions
By utilising new tools such as portable ultrasound machines,
identification of serological markers, and good international
standards on child growth, our understanding of the causes and
consequences of childhood hepatosplenomegaly in the tropics has
improved. It is clear that hepatosplenomegaly associated with
schistosomiasis mansoni, in the absence of periportal fibrosis, is a
distinct widespread morbidity amongst school-aged children that
can have severe health consequences. Advances in immunological
reagents and instrumentation allow us to measure many more
mediators in small quantities of plasma or cell culture superna-
tants, giving insight into potential dysregulation of a pro-
inflammatory process. The continuation of good epidemiological
study design techniques, in combination with new satellite GIS
techniques, has highlighted the importance of confounders or
modifiers. A particularly important finding is the role of chronic
exposure to malaria in exacerbation of S. mansoni–associated
hepatosplenomegaly, through the potential modulation of the
inflammatory process. Exacerbation by chronic exposure to
malaria underlines the importance of assessing as many potential
confounders as is logistically feasible. As Walter and McGregor
noted in 1960, the aetiology of childhood hepatosplenomegaly is
complex, but we now have the computational and statistical tools
to take a more holistic approach. To study an infection in isolation
is an opportunity missed to broaden our knowledge of this so-
called subtle morbidity, its underlying causes, mechanisms, and
long-term health consequences. Equipped with this knowledge,
rather than burdening children with the residual consequences of
treating causative agents in isolation, informed integrated public
health policies could be designed with the aim of maximising
alleviation from this widespread and debilitating morbidity.
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